Skip to content

Early Diagnosis Of Blood Cancers In AVBRH

Early Diagnosis Of Hematological Malignancies In AVBRH

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/06/054291
Enrollment
55
Registered
2023-06-21
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C910- Acute lymphoblastic leukemia [ALL] Health Condition 2: C930- Acute monoblastic/monocytic leukemia Health Condition 3: C920- Acute myeloblastic leukemia Health Condition 4: C91- Lymphoid leukemia Health Condition 5: C812- Mixed cellularity Hodgkin lymphoma Health Condition 6: C900- Multiple myeloma Health Condition 7: C96Z- Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue

Interventions

None listed

Sponsors

Datta Meghe Institiute of Higher Education Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients presenting with Severe pallor,Loss of weight,Loss of appetite ,Night sweats,Any active bleeding,Organomegaly,Lymphadenopathy,Evening rise of temperature,Pain abdomen,Generalized weakness,Chronic bone pain.

Exclusion criteria

Exclusion criteria: 1)Known or proven case of Leukemia. 2)Hematological cancers undergoing Chemotherapy or Radiotherapy. 3)Relapse of the disease.

Design outcomes

Primary

MeasureTime frame
Whether early diagnosis & typing of hematological malignancies help in patient prognosis & treatment modality.Timepoint: At diagnosis & 1 year post diagnosis.

Secondary

MeasureTime frame
Early diagnosis of hematological malignancies along with further sub typing wherever possible.Timepoint: At diagnosis & 1 year post diagnosis.

Countries

India

Contacts

Public ContactPriya Chatterjee

Jawaharlal Nehru Medical College And Hospital

keshaohiwale5@gmail.com9823749905

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026